What Makes Us Different
Reignite MedTech & Pharma Ltd. is a Hong Kong-registered consulting, trading, and investment company.
With more than 30 years of global experience in research and development, manufacturing, operations, and marketing, we specialize in the medical device and pharmaceutical sectors, delivering world-class products and services.
Our business operations span Mainland China and Hong Kong, Europe, North America, ASEAN, and other international markets.
Mainland China/
Europe/
North America
Medical Device and Pharmaceutical Industries
Consulting, Trading & Investment
ABOUT US
—— Milestones ——
Ongoing Projects
We are committed to excellence in health care. Our providers collaborate to deliver comprehensive, personalized care to all.
VitaNova Project
Focused on the innovation and development of high-end medical devices, VitaNova Medical is currently valued at approximately RMB 100 million.
Opterion Health Product Licensing Project
Opterion Health AG, a Swiss pharmaceutical company, is currently conducting clinical trials and has signed an LOI with Reignite for an exclusive partnership in the Greater China region.
Licensing Projects
Oral Therapy for Preventing Urinary Catheter Encrustation
Addresses the challenge of long-term urinary catheter encrustation and blockage. Simple to administer with demonstrated effectiveness.
OEM Projects
PA Company is a Swiss innovator developing pharmaceutical and medical device products, currently advancing a Class III sterile ultrafine dry-powder medical device for the Chinese market.
Licensing Projects
Ventilator
Seeking a strategic partner for the China market, with a preference for an exclusive model that includes local manufacturing, regulatory registration, and commercialization.
M&A Targets
All four targets are leading multinational medical supply companies. The opportunities involve the sale of the entire business, with estimated valuations ranging from EUR 30 million to 100 million.
—— Milestones ——
Ongoing Projects
We are committed to excellence in health care. Our providers collaborate to deliver comprehensive, personalized care to all.
RES-O11 Project
Res-O11 is an innovative therapeutic technology designed to provide a novel treatment option for patients with hypercapnia.
2026
07-06
Opterion Health AG is an international biopharmaceutical company focused on the development of innovative therapeutics. Its lead product, OPT101, is currently undergoing clinical trials in Europe. ...
PA Company is a Swiss enterprise specializing in the research and development of innovative pharmaceutical and medical device products. Its Class III sterile ultrafine dry-powder medical device is ...
2026-07-14
The target is a wholly foreign-owned manufacturing facility in China operated by a multinational medical supplies company. It has a well-established production system and comprehensive quality mana...
2026-06-07
—— Milestones ——
Success Stories
|
|